Bristol-Myers Squibb Co. (BMY)

49.43
NYSE : Health Technology
Prev Close 49.61
Day Low/High 49.28 / 50.35
52 Wk Low/High 42.48 / 63.69
Avg Volume 12.61M
Exchange NYSE
Shares Outstanding 1.64B
Market Cap 81.15B
EPS 3.00
P/E Ratio 12.66
Div & Yield 1.64 (3.31%)
Jim Cramer: Avoid the Naked CEOs When the Tide Goes Out

Jim Cramer: Avoid the Naked CEOs When the Tide Goes Out

There is clear divergence between the best and the worst performers in each sector this earnings season.

Consider These Diagnostic Testing Firms

Consider These Diagnostic Testing Firms

Diagnostic firms can have an advantage of recurring revenue streams.

Bristol-Myers Is Confronting Overhead Resistance and a Lack of Aggressive Buying

Bristol-Myers Is Confronting Overhead Resistance and a Lack of Aggressive Buying

Let's take a fresh look at the charts.

All The President's Men (and Mess)

* The Cohen plea is a potentially serious threat to the Presidency and to the Bull Market * The Manafort and Cohen indictments are a blow to the Republican Party and raises the odds of a "Blue Wave" in November * Though the market did well under Pre...

Jim Cramer: What Does Politics Have to Do With Johnson & Johnson's P/E?

Jim Cramer: What Does Politics Have to Do With Johnson & Johnson's P/E?

The answer is plenty, but you can't trade that.

Eight Stocks That Are Poised to Change Direction

Eight Stocks That Are Poised to Change Direction

Harley-Davidson is among these names showing technical reversal patterns over the past week.

Tesla, Boeing and Merck Among Companies Hurt by Latest Tariffs

Tesla, Boeing and Merck Among Companies Hurt by Latest Tariffs

The latest announcement from the U.S. Trade Representative's office is chilling reading for free trade supporters.

ASCO's Big Winner: Loxo Oncology

ASCO's Big Winner: Loxo Oncology

Every year there are 'winners' and 'losers' from the biggest confab around oncology of the year.

In a Changing World, Past Performance May Not Be Predictive of the Future

* In a paperless and cloudy world, are investors and citizens as safe as the markets assume we are? * In a flat, networked and interconnected world, is it even possible for America to be an "oasis of prosperity" and a driver or engine of global econ...

When the Stock Is the Only Option

When the Stock Is the Only Option

Options spreads aren't tradable with some small biotechs, making shares the only way to play.

Surveying the M&A Landscape in Biotech

Surveying the M&A Landscape in Biotech

Who might be in play in the quarters ahead?

4 Keys to Staying Alive in Tough Markets -- And How I'm Playing 3 Big Tech Names

4 Keys to Staying Alive in Tough Markets -- And How I'm Playing 3 Big Tech Names

KLA-Tencor, Microsoft and Intel all report earnings after the close Thursday.

Drug Maker Bristol-Myers Squibb Is Having a Bad Reaction to Selling

Drug Maker Bristol-Myers Squibb Is Having a Bad Reaction to Selling

Let's look at the charts this afternoon.

Jim Cramer: Possible Jarring Events Will Be Hard for the Market to Ignore

Jim Cramer: Possible Jarring Events Will Be Hard for the Market to Ignore

Let's puzzle over Syria and the possibility of another 'Saturday Night Massacre.'

Jim Cramer: Fed Minutes and Oil Hit the Market

Jim Cramer: Fed Minutes and Oil Hit the Market

Why you can't blame the president for Wednesday's weakness.

Jim Cramer: The Fundamentals on the Eve of Earnings Seem Pretty Darned Good

Jim Cramer: The Fundamentals on the Eve of Earnings Seem Pretty Darned Good

But If you want to know what I think could work the loudest here? How about Amazon?

Women's History Month: Nancy Lieberman -- Still Law Firm's Youngest Partner Ever

Women's History Month: Nancy Lieberman -- Still Law Firm's Youngest Partner Ever

For Women's History Month, Alpha Rising sat down with Nancy Lieberman, Of Counsel at Skadden, Arps. She was and still is the youngest person to ever make partner at her firm. She has worked on some of the biggest M&A deals in history -- and we should mention -- she's in a wheelchair and barely as use of her hands. Feel like a slacker yet? Good. Watch.

Bristol-Myers Squibb Could Trade Sideways Till the Bull Returns

Bristol-Myers Squibb Could Trade Sideways Till the Bull Returns

Let's check out the charts and indicators for some guidance.

Jim Cramer: Will the Techs Be Challenged, Too?

Jim Cramer: Will the Techs Be Challenged, Too?

The theft of intellectual property can be confronted by a Section 301 challenge directly from the trade representative.

Jim Cramer: Here's 10 Things to Watch For

Jim Cramer: Here's 10 Things to Watch For

You just have to look at it like a drill.

Jim Cramer: Here's 10 Things to Watch For

Jim Cramer: Here's 10 Things to Watch For

You just have to look at it like a drill.

Rock and Roll: Bristol-Myers Squibb Is Breaking Out

Rock and Roll: Bristol-Myers Squibb Is Breaking Out

You can buy it here or you can buy it higher.

Cramer: Finding Winning Stocks Is Like Finding a Needle in a Haystack

Cramer: Finding Winning Stocks Is Like Finding a Needle in a Haystack

It is often better advice just to sit on your hands because we know from yesterday that any rally is suspect or ephemeral at best.

The Easy Money in This Market Has Been Made

The Easy Money in This Market Has Been Made

The truth is, the environment has changed.

The Case For Buying Bristol-Myers Squibb

The Case For Buying Bristol-Myers Squibb

After a sideways consolidation, look to add to this drug maker.

Jim Cramer: Breakouts Are the New Normal for This Stock Market

Jim Cramer: Breakouts Are the New Normal for This Stock Market

We have seen this pattern many times in the last few months, and it is a surreal pattern for traders.